Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Ginkgo Bioworks Holdings (DNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: DNA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.67
1 Year Target Price $8.67
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 3 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.64% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 561.91M USD | Price to earnings Ratio - | 1Y Target Price 8.67 |
Price to earnings Ratio - | 1Y Target Price 8.67 | ||
Volume (30-day avg) 6 | Beta 1.26 | 52 Weeks Range 5.00 - 16.85 | Updated Date 07/17/2025 |
52 Weeks Range 5.00 - 16.85 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -198.84% | Operating Margin (TTM) -182.09% |
Management Effectiveness
Return on Assets (TTM) -16.99% | Return on Equity (TTM) -57.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 499445857 | Price to Sales(TTM) 2.37 |
Enterprise Value 499445857 | Price to Sales(TTM) 2.37 | ||
Enterprise Value to Revenue 2.1 | Enterprise Value to EBITDA -1.79 | Shares Outstanding 46344600 | Shares Floating 40286320 |
Shares Outstanding 46344600 | Shares Floating 40286320 | ||
Percent Insiders 6.88 | Percent Institutions 79.34 |
Upturn AI SWOT
Ginkgo Bioworks Holdings
Company Overview
History and Background
Ginkgo Bioworks Holdings, Inc. was founded in 2008. It went public in 2021 via a SPAC merger with Soaring Eagle Acquisition Corp. Ginkgo's core mission is to make biology easier to engineer, enabling applications across diverse industries.
Core Business Areas
- Foundry Services: Ginkgo's foundry offers a platform for designing and engineering organisms for various applications, from creating novel enzymes to producing sustainable materials.
- Cell Engineering: Ginkgo specializes in engineering cells to perform specific functions, such as producing biofuels, pharmaceuticals, and other high-value products.
- Biosecurity: Through Concentric by Ginkgo, the company provides biosecurity solutions, including pathogen monitoring and outbreak response, to help prevent and mitigate the spread of infectious diseases.
Leadership and Structure
Ginkgo Bioworks is led by CEO Jason Kelly. The organizational structure includes teams focused on foundry operations, software development, strain engineering, biosecurity, and commercial partnerships.
Top Products and Market Share
Key Offerings
- Foundry Platform: Ginkgo's main offering is its foundry platform, which allows customers to design and engineer organisms. The market share is difficult to ascertain precisely due to the nascent nature of the synthetic biology market. Competitors include Amyris and Zymergen (now part of Ginkgo).
- Concentric (Biosecurity): Concentric provides biosecurity services, including COVID-19 testing and pathogen monitoring. Market share is competitive with companies like Illumina and Roche offering similar testing services.
Market Dynamics
Industry Overview
The synthetic biology industry is rapidly growing, driven by increasing demand for sustainable and bio-based products. It encompasses areas like biopharmaceuticals, agriculture, and industrial biotechnology.
Positioning
Ginkgo is a leading player in the synthetic biology market, offering a platform for cell programming. Its competitive advantage lies in its scale, breadth of capabilities, and data assets.
Total Addressable Market (TAM)
The TAM for synthetic biology is estimated to be in the hundreds of billions of dollars. Ginkgo is positioning itself to capture a significant portion of this market by offering a comprehensive platform for cell engineering.
Upturn SWOT Analysis
Strengths
- Leading platform for cell programming
- Extensive data assets and expertise
- Diverse customer base
- Strategic acquisitions
- Strong intellectual property portfolio
Weaknesses
- High operating expenses
- Dependence on key partners
- Unproven profitability at scale
- Complexity of the technology
Opportunities
- Expanding applications of synthetic biology
- Increasing demand for sustainable products
- Partnerships with established companies
- Government funding and support
- Advancements in AI and automation
Threats
- Competition from other synthetic biology companies
- Regulatory hurdles
- Ethical concerns
- Economic downturns
- Technological disruptions
Competitors and Market Share
Key Competitors
- DNA
- AMRS
- TMO
Competitive Landscape
Ginkgo's advantage is its horizontal platform approach, while competitors may focus on specific applications. Challenges include scaling production and demonstrating profitability.
Major Acquisitions
Zymergen
- Year: 2022
- Acquisition Price (USD millions): 300
- Strategic Rationale: Expanded Ginkgo's capabilities in strain engineering and data assets, and eliminated a key competitor.
Growth Trajectory and Initiatives
Historical Growth: Ginkgo has experienced rapid growth in revenue and customer base since its founding.
Future Projections: Analyst estimates suggest continued revenue growth for Ginkgo, driven by increased adoption of its platform.
Recent Initiatives: Ginkgo has focused on expanding its foundry capabilities, forming strategic partnerships, and developing new biosecurity solutions.
Summary
Ginkgo Bioworks is a leading company in the synthetic biology space, offering a comprehensive platform for cell engineering. Its strengths include its extensive data assets, strategic acquisitions, and diverse customer base. Challenges include high operating expenses and achieving profitability at scale. Future growth depends on expanding applications of synthetic biology and forming strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ginkgo Bioworks Holdings
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-04-19 | Founder, CEO & Director Dr. Jason Kelly Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 834 | Website https://www.ginkgo.bio |
Full time employees 834 | Website https://www.ginkgo.bio | ||
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.